Основная статистика
| LEI | 529900HGKY864E4Y9014 |
| CIK | 1341235 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aldeyra Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 19, 2025 |
Exhibit 99.1 Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa LEXINGTON, Mass., August 19, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigm |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2025 |
Sixth Amendment to Lease between WLC Three VI, L.L.C. and the Registrant, dated as of April 1, 2025. Exhibit 10.1 SIXTH AMENDMENT TO LEASE AGREEMENT THIS SIXTH AMENDMENT TO LEASE AGREEMENT is made and entered into on April 1, 2025, by and between 131 Hartwell LLC, a Massachusetts limited liability company ("Landlord") and Aldeyra Therapeutics, Inc. a Delaware corporation ("Tenant"). RECITALS: A. The Landlord and the Tenant executed a Lease Agreement dated September 20, 2017, a First Amendment dat |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| July 17, 2025 |
Exhibit 99.1 Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease PDUFA Target Action Date December 16, 2025 Lexington, Mass., July 17, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (ND |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 26, 2025 |
Exhibit 99.1 News Release Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Lexington, Mass., June 26, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Adm |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 17, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 17, 2025 |
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Exhibit 99.1 News Release Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Lexington, Mass., June 17, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 (June 10, 2025) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorpora |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| May 6, 2025 |
Topline Data Release and NDA Resubmission Plan REPROXALAP FOR THE POTENTIAL TREATMENT OF DRY EYE DISEASE May 6, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. |
|
| May 6, 2025 |
Exhibit 99.2 News Release Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatm |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 (May 5, 2025) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| April 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| April 17, 2025 |
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors Exhibit 99.1 Aldeyra Therapeutics Appoints Chip Clark to Board of Directors Lexington, Mass., April 17, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company’s board of directors. “Chip posses |
|
| April 3, 2025 |
Exhibit 99.2 News Release Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease • Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 • Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expecte |
|
| April 3, 2025 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| April 3, 2025 |
EX-99.1 Exhibit 99.1 C O N F E R E N C E C A L L Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update April 3, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025 2 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Excha |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-36332 |
|
| February 28, 2025 |
Aldeyra Therapeutics, Inc. Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97 ALDEYRA THERAPEUTICS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Subsidiaries of Aldeyra Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF ALDEYRA THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Organization Helio Vision, LLC United States of America Helio Vision Germany GmbH Germany Aldeyra Securities Corporation United States of America |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-36332 ALDEYRA THERAPEUTIC |
|
| February 28, 2025 |
Aldeyra Therapeutics, Inc. Amended and Restated Insider Trading Policy Exhibit 19.1 Aldeyra Therapeutics, Inc. Amended and Restated Insider Trading Policy (Effective as of February 28, 2023) Table of Contents Page Introduction 1 A. Legal Prohibitions on Insider Trading 1 B. Detection and Prosecution of Insider Trading 1 C. Penalties for Violation of Insider Trading Laws and This Policy 2 D. Compliance Officer 3 E. Reporting Violations 3 F. Personal responsibility 3 P |
|
| February 28, 2025 |
Expansion Side Letter Agreement: Aldeyra & AbbVie Collaboration Update Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. November 15, 2024 Aldeyra Therapeutics, Inc. 131 Hartwell Avenue, Suite 320 Lexington, MA 02421 Re: Aldeyra and Reproxalap commercialization funding and option period extension To Who |
|
| February 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aldeyra Therapeutics, Inc. |
|
| February 28, 2025 |
Exhibit 10.25 Execution Version FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of October 28, 2024 (the “Fifth Amendment Effective Date”), is entered into by and among ALDEYRA THERAPEUTICS INC., a Delaware corporation (“Aldeyra”), Helio Vision, LLC, a Delaware limited liability company, and each of Aldeyra’s Qualified |
|
| November 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 (November 15, 2024) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of i |
|
| November 18, 2024 |
Exhibit 99.1 Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement PDUFA Date is April 2, 2025 Lexington, Mass., November 18, 2024 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted Ne |
|
| November 14, 2024 |
ALDX / Aldeyra Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 7, 2024 |
Exhibit 10.4 MASTER SERVICES AGREEMENT This Master Services Agreement (the “Agreement”) is made effective as of August 15, 2024 (the “Effective Date”), by and between Aldeyra Therapeutics, Inc., a Delaware corporation, with its principal place of business being 131 Hartwell Avenue, Suite 320, Lexington, MA 02421 (the “Company”) and Danforth Global, Inc., a Delaware corporation, with its principal |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALD |
|
| November 7, 2024 |
Separation Agreement The following agreement (“Agreement”) between Bruce Greenberg (“you,” or “your,”) and Aldeyra Therapeutics, Inc. |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commiss |
|
| October 3, 2024 |
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Exhibit 99.1 News Release Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Lexington, Mass., October 3, 2024 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Dr |
|
| October 2, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 (September 30, 2024) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of in |
|
| October 2, 2024 |
Exhibit 10.2 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of September 30, 2024 (the “Fourth Amendment Effective Date”), is entered into by and among ALDEYRA THERAPEUTICS INC., a Delaware corporation (“Aldeyra”), Helio Vision, LLC, a Delaware limited liability company, and each of Aldeyra’s Qualified Subsidiaries |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 (August 29, 2024) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of inc |
|
| August 8, 2024 |
Exhibit 99.1 Dry Eye Disease Chamber Phase 3 Clinical Trial of Reproxalap REPROXALAP CLINICAL DEVELOPMENT AND REGULATORY UPDATE August 8, 2024 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2024 TOP - LINE RESULTS 2 Disclaimers and Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 2 |
|
| August 8, 2024 |
Exhibit 99.2 News Release Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap New Drug Application Resubmission Anticipated in 2024 Lexington, Mass., August 08, 2024 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabol |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| August 1, 2024 |
Exhibit 10.1 Execution Version THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this "Amendment"), dated as of April 29, 2024 (the "Third Amendment Effective Date"), is entered into by and among ALDEYRA THERAPEUTICS INC., a Delaware corporation ("Aldeyra"), Helio Vision, LLC, a Delaware limited liability company, and each of Aldeyra's Qualified Su |
|
| August 1, 2024 |
Open Market Sale AgreementSM by and between the Company and Jefferies LLC, dated August 1, 2024. Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 1, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Aldeyra Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s commo |
|
| August 1, 2024 |
Up to $75,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277753 PROSPECTUS SUPPLEMENT (To Prospectus dated April 24, 2024) Up to $75,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, dated August 1, 2024, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the offer and sale of shares of our common stock, par value $0.001 per share, from ti |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| August 1, 2024 |
Exhibit 10.2 FIFTH AMENDMENT TO LEASE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT is made and entered into on April 29, 2024, by and between 131 Hartwell LLC, a Massachusetts limited liability company ("Landlord") and Aldeyra Therapeutics, Inc. a Delaware corporation ("Tenant"). RECITALS: A. The Landlord and the Tenant executed a Lease Agreement dated September 20, 2017, a First Amendment da |
|
| June 20, 2024 |
Exhibit 99.1 News Release Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable Live Webcast Scheduled to Begin at 8:00 a.m. ET Today Lexington, Mass., June 20, 2024 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 13, 2024 |
Exhibit 99.1 Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024 LEXINGTON, Mass.-(BUSINESS WIRE) – June 13, 2024 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative th |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 (June 4, 2024) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporati |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| April 25, 2024 |
Exhibit 99.2 Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day Live Webcast Scheduled to Begin at 9 am EDT Today LEXINGTON, Mass.-(BUSINESS WIRE)-Apr. 25, 2024- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2024 |
Exhibit 99.1 202 4 R e s e a r c h & D e v e l o p m e n t D a y C O R P O A T E O A p r i l 25 , 202 4 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2024 Todd C. Brady, M.D., Ph.D., Chief Executive Officer, Aldeyra Therapeutics W e l c o m e a n d O p e n i n g R e m a r k s 3 D i sc l a i m e r s a n d F o r w a r d - L oo k i n g S t a t e m e n t s This presentation and various remarks which may b |
|
| April 22, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 22, 2024 |
Aldeyra Therapeutics, Inc. 131 Hartwell Avenue Suite 320 Lexington, MA 02421 Aldeyra Therapeutics, Inc. 131 Hartwell Avenue Suite 320 Lexington, MA 02421 April 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Aldeyra Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-277753) Dear Ms. Gama: Pursuant to Rules 460 and 461 under the Securities Act of 1933 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| March 28, 2024 |
Exhibit 99.1 News Release Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease Lexington, Mass., March 28, 2024 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announc |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Aldeyra Therapeutics, Inc. |
|
| March 7, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aldeyra Therapeutics, Inc. |
|
| March 7, 2024 |
Exhibit 10.14 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease ("Fourth Amendment") is dated as of November 22, 2023 by and between 131 Hartwell LLC, a Massachusetts limited liability company ("Landlord"), successor-in-interest to WLC Three VI, L.L.C., a Delaware limited liability company ("Original Landlord") and Aldeyra Therapeutics, Inc. ("Tenant"), a Delaware corporation. WHEREAS, Orig |
|
| March 7, 2024 |
Exclusive Option Agreement, between the Registrant and AbbVie Inc., dated as of October 31, 2023 Exhibit 10.26 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE OPTION AGREEMENT This Exclusive Option Agreement (the “Agreement”) is made and entered into as of October 31, 2023 (the “Effective Date”) by and between Al |
|
| March 7, 2024 |
Aldeyra Therapeutics, Inc. Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97 ALDEYRA THERAPEUTICS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
Subsidiaries of Aldeyra Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF ALDEYRA THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Organization Helio Vision, LLC United States of America Helio Vision Germany GmbH Germany |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-36332 ALDEYRA THERAPEUTIC |
|
| February 14, 2024 |
ALDX / Aldeyra Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 13, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| February 13, 2024 |
Exhibit 99.1 Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW February 2024 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including state |
|
| February 13, 2024 |
ALDX / Aldeyra Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0221-aldeyratherapeuticsin.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Aldeyra Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 01438T106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pur |
|
| January 4, 2024 |
Exhibit 99.1 Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, proposed expansion to include pediatric patients expected to be submitted to the US Food and Drug Administrati |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commiss |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| December 19, 2023 |
Exhibit 99.2 Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis Statistically significant improvement from baseline observed in investigator-assessed Eczema Area and Severity Index (EASI, p=0.0006) and Investigator Global Assessment (IGA, p<0.0001) EASI 75% improvement (EASI-75) t |
|
| December 19, 2023 |
Exhibit 99.1 Top-Line Results from thePhase 2 Clinical Trial of ADX-629in Atopic Dermatitis DATA RELEASE December 19, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1 |
|
| November 28, 2023 |
Exhibit 99.1 C O N F E R E N C E C A L L Reproxalap for the Treatment of Dry Eye Disease Regulatory Update November 28, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 2 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 (November 27, 2023) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of i |
|
| November 28, 2023 |
Exhibit 99.2 Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease • Additional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease • Special Protocol Assessment Submitted on November 16, 2023 for Dry Eye Disease Chamber Crossover |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALDEYRA THERAPEUTICS, INC. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALD |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 S-8 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 (October 31, 2023) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of inc |
|
| October 19, 2023 |
ALDX / Aldeyra Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d476292dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) October 16, 2023 (Date of Event Which Requires Filing of this Statemen |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 (October 10, 2023) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of inc |
|
| October 4, 2023 |
ALDX / Aldeyra Therapeutics Inc / Knoll Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Aldeyra Therapeutics Inc (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 01438T 10 6 (CUSIP Number) |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| August 3, 2023 |
Exhibit 10.1 Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan (As Adopted on May 18, 2023) DOCPROPERTY"SWDocID" GDSVF&H\8762776.11 Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Plan was adopted by the Board on May 18, 2023, and will become effective immediately upon its approval by the Company’s stockholders. The purpose of the Plan is to promote the long- |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 (June 30, 2023) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporat |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 29, 2023 |
Exhibit 99.1 Top-Line Results from thePhase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa DATA RELEASE June 29, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of |
|
| June 29, 2023 |
Exhibit 99.2 Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa Best Corrected and Low‑Light Visual Acuity Statistically Significantly Improved As Assessed by Electroretinography, Time to Retinal Response Statistically Significantly Improved As Assessed by Macular and Dark-Adapted Perimetry, Retin |
|
| June 27, 2023 |
Exhibit 99.1 Top-Line Results from thePhase 2 Clinical Trial ofADX-629 in Chronic Cough DATA RELEASE June 27, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and |
|
| June 27, 2023 |
Exhibit 99.2 Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough Relative to Placebo, Statistical Significance Achieved for Reduction in Awake Cough Frequency (P=0.01), 24‑Hour Cough Frequency (P=0.001), Awake Cough Count (P=0.001), and 24‑Hour Cough Count (P=0.001) ADX-629 Was Well Tolerated and |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2023 |
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 Exhibit 99.1 Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 Based on U.S. Food & Drug Administration (FDA) Determination of Lack of Adequate and Well Controlled Investigations in the Scientific Literature, Complete Response Letter Received for New Drug Application (NDA) of ADX-2191 (methotrexate injection, USP) for the Treatment of Primary Vitreoretinal Lymphoma (PVRL) Due to Shortage |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 15, 2023 |
Exhibit 99.1 Top-Line Results from thePhase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis DATA RELEASE June 15, 2023 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| June 15, 2023 |
Exhibit 99.2 Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (P<0.0001) Statistical Significance Achieved for Key Secondary Endpoint of Ocular Redness (P |
|
| May 23, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| May 4, 2023 |
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Quarter of 2023 Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Chronic Cough Expected in the Second Quarter of 2023 Top-Line Results from the Phase 3 INVIGORATE-2 Tr |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| March 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| March 9, 2023 |
Offer Letter, effective as of November 27, 2019, between the Registrant and Bruce Greenberg. Exhibit 10.24 Aldeyra Therapeutics, Inc. 131 Hartwell Avenue, Suite 320 Lexington, MA 02421 November 26, 2019 Bruce Greenberg xx xxxxx xxxxx xxxxxxxx, xx xxxxx Dear Bruce: Aldeyra Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Vice President, Controller and you will initially report to the Company’s Chief Financ |
|
| March 9, 2023 |
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights NDA Priority Review PDUFA Date for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma is June 21, 2023 NDA PDUFA Date for Reproxalap for the Treatment of Dry Eye Disease is November 23, 2023 Top-Line Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctiviti |
|
| March 9, 2023 |
Power of Attorney (included in the signature page to the registration statement). S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aldeyra Therapeutics, Inc. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-36332 ALDEYRA THERAPEUTIC |
|
| March 9, 2023 |
Subsidiaries of Aldeyra Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF ALDEYRA THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Organization Helio Vision, LLC United States of America Helio Vision Germany GmbH Germany |
|
| March 2, 2023 |
Exhibit 99.1 FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma PDUFA Date is June 21, 2023 Planned U.S. Launch of ADX-2191 in Second Half of 2023, Pending Approval by the FDA ADX-2191 with Potential to be the First FDA-Approved Drug Available for Patients Suffering from Primary Vitreoretinal Lymphoma LEXINGTON, Mass.-(BUSINESS WIRE)-M |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2023 |
ALDX / Aldeyra Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 7, 2023 |
Exhibit 99.1 Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease PDUFA Date is November 23, 2023 First-in-Class RASP Modulator Represents a Potential New Therapeutic Paradigm for Patients Suffering from Dry Eye Disease LEXINGTON, Mass.-(BUSINESS WIRE)-February 7, 2023-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today ann |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 (December 22, 2022) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of i |
|
| December 27, 2022 |
Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of December 22, 2022, and effective as of December 31, 2022 (the ?Second Amendment Effective Date?), is entered into by and among ALDEYRA THERAPEUTICS INC., a Delaware corporation (?Aldeyra?), Helio Vision, LLC, a Delaware limited liability company, and eac |
|
| December 21, 2022 |
Exhibit 99.1 Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma LEXINGTON, Mass.-(BUSINESS WIRE)-December 21, 2022-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (meth |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2022 |
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Exhibit 99.1 Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Primary Vitreoretinal Lymphoma New Drug Application (NDA) for ADX-2191 Expected to be Submitted as Soon as the End of 2022 Company Intends to Request Priority Review Designation LEXINGTON, Mass.-(BUSINESS WIRE)-December 1, 2022-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today a |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| November 29, 2022 |
Exhibit 99.1 Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease LEXINGTON, Mass.-(BUSINESS WIRE)-November 29, 2022-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topic |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALD |
|
| November 10, 2022 |
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights New Drug Application (NDA) Submission of Reproxalap for the Treatment of Dry Eye Disease on Schedule for the Fourth Quarter of 2022 Pre-NDA Meeting with the U.S. Food and Drug Administration (FDA) Scheduled for the Fourth Quarter of 2022 to Discuss NDA Submission of ADX-2191 for the Treat |
|
| October 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commiss |
|
| October 6, 2022 |
Exhibit 99.1 Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy October 6, 2022 NASDAQ: ALDX ?Aldeyra Therapeutics, Inc. 2022 2 This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securi |
|
| October 6, 2022 |
Exhibit 99.2 Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy ADX-2191 Statistically Superior to Historical Control for Primary Endpoint of Prevention of Retinal Detachment (P=0.024) Numerical Superiority of ADX-2191 over Routine Surgical Care Achieved for Majority of Secondary, Exploratory, and Safety Endpoints ADX-2191 |
|
| September 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Comm |
|
| September 14, 2022 |
Exhibit 99.1 Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Scheduled for the Fourth Quarter of 2022 Results from Part 1 of the Phase 3 GUARD Tria |
|
| August 5, 2022 |
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights Pre-NDA (New Drug Application) Meeting with the U.S. Food and Drug Administration (FDA) Scheduled for the Third Quarter of 2022 to Discuss NDA Submission of Reproxalap for the Treatment of Dry Eye Disease Pre-NDA Meeting with the FDA Planned for the Second Half of 2022 to Discuss NDA Sub |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA |
|
| July 12, 2022 |
Exhibit 99.1 Top-Line Results from theDry Eye Disease Chamber Crossover Trial of Reproxalap July 12, 2022 NASDAQ: ALDX ?Aldeyra Therapeutics, Inc. 2022 2 This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, |
|
| July 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissio |
|
| July 12, 2022 |
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial Exhibit 99.2 Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005) Schirmer Test ?10mm Responder Analysis Multiplicity-Controlled Secondary Endpoint Achieved (P=0.0361) Secondary Endpoints Achieved for All Symptoms Assessed: |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 (June 7, 2022) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporati |
|
| June 8, 2022 |
Exhibit 99.1 Aldeyra Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease June 8, 2022 NASDAQ: ALDX ©Aldeyra Therapeutics, Inc. 2022 Aldeyra This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act o |
|
| June 8, 2022 |
Exhibit 99.2 Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Resul |
|
| May 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2022 |
Exhibit 99.1 Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxalap Over Vehicle in Ocular Redness in Completed TRANQUILITY Trial LEXINGTON, Mass.-(BUSINESS WIRE)-May 24, 2022-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) tod |
|
| May 18, 2022 |
Exhibit 99.1 Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness Post-Hoc Analysis Using Computer Automated Grading Indicated that Reproxalap is Statistically Superior to Vehicle (p=0.020) in Reducing Dr |
|
| May 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected in Second Quarter of 2022 Results from Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy and Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Half |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 (April 25, 2022) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorpo |
|
| April 28, 2022 |
Aldeyra Therapeutics Announces Chief Financial Officer Transition Exhibit 99.1 Aldeyra Therapeutics Announces Chief Financial Officer Transition LEXINGTON, Mass.-(BUSINESS WIRE)-April 28, 2022-Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to serve as CFO and Treasurer until May 10, 2022 (the Resi |
|
| April 25, 2022 |
DEFA14A 1 d429845ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| April 25, 2022 |
DEF 14A 1 d429845ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 29, 2022 |
EX-99.1 ADX-629: A First-in-Class, Oral RASP Modulator for the Treatment of Systemic Disease 2022 Research & Development Day March 29, 2022 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2022 Exhibit 99.1 Welcome and Opening Remarks Todd C. Brady, M.D., Ph.D., Chief Executive Officer March 29, 2022 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2022 Disclaimers and Forward-Looking Statements This presentati |
|
| March 29, 2022 |
Exhibit 99.2 News Release Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day ? Signs of Pharmacodynamic and Clinical Activity Generated Across Three Phase 2 Proof-of-Concept Clinical Trials in Patients with Immune-Mediated Disease; No Safety or Tolerability Issues Observed ? ADX-629 to Be Advanced to New Development Indications: Et |
|
| March 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2022 |
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Exhibit 99.1 Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Top-Line Data from Proof-of-Concept Clinical Trials of ADX-629 in Multiple Systemic Indications Expected by the End of March 2022 Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected Mid-2022 Results from Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTIC |
|
| March 17, 2022 |
AMENDMENT NO. 2 TO THE OFFER LETTER Exhibit 10.19 (b) This Amendment No. 2 to the Offer Letter (the ?Offer Letter?) is entered into by and between Aldeyra Therapeutics, Inc. (the ?Company?) and Stephen G. Machatha, Ph.D. effective as of March 23, 2021. WHEREAS, you and the Company previously entered into that Offer Letter, dated October 15, 2015, which governs the terms of your employment by the C |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 S-8 1 d335510ds8.htm S-8 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction of incorporati |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aldeyra Therapeutics, Inc. |
|
| March 17, 2022 |
AMENDMENT NO. 1 TO THE OFFER LETTER Exhibit 10.19 (a) This Amendment No. 1 to the Offer Letter (the ?Offer Letter?) is entered into by and between Aldeyra Therapeutics, Inc. (the ?Company?) and Stephen G. Machatha, Ph.D. effective as of January 1, 2018. WHEREAS, you and the Company previously entered into that Offer Letter, dated October 15, 2015, which governs the terms of your employment by the |
|
| March 17, 2022 |
Exhibit 10.19 Aldeyra Therapeutics, Inc. 131 Hartwell Avenue, Suite 320 Lexington, MA 02421 October 21, 2015 Stephen G. Machatha, Ph.D. Dear Stephen, Aldeyra Therapeutics, Inc. (the ?Company?) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Vice President of Chemistry, Manufacturing and Controls (CMC) and you will initially report to the Company?s |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
ALDX / Aldeyra Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d320195dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| January 4, 2022 |
ALDX / Aldeyra Therapeutics Inc / Domain Partners VI, L.P. - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01438T106 (CUSIP Number) December 31, 2021 Date |
|
| December 21, 2021 |
Exhibit 99.1 December 20, 2021 Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amend |
|
| December 21, 2021 |
Exhibit 99.2 Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease ? TRANQUILITY Primary Endpoint of Ocular Redness Not Met, but Statistical Significance Achieved for Secondary Endpoint of Schirmer Test (p=0.0001), an Approvable Sign of Dry Eye Disease ? Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer T |
|
| December 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 (December 20, 2021) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of i |
|
| November 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| November 9, 2021 |
Exhibit 99.1 Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance Top-Line Results from TRANQUILITY Expected This Quarter Together with Recently Completed Phase 2 Clinical Trial, Positive Ocular Redness Results from TRANQUILITY Could Satisfy NDA Submission Requirements as |
|
| November 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| November 2, 2021 |
EX-99.1 2 d240887dex991.htm EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double- Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease LEXINGTON, Mass., November 2, 2021 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced achievement of the primary endpoint of ocular redness in a randomized, do |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDE |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| October 28, 2021 |
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights EX-99.1 2 a52517114ex991.htm EXHIBIT 99.1 Exhibit 99.1 Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021 Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in |
|
| October 28, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (?Third Amendment?) is dated as of August 12, 2021 by and between 131 Hartwell LLC, a Massachusetts limited liability company (?Landlord?), successor-in-interest to WLC Three VI, L.L.C., a Delaware limited liability company (?Original Landlord?) and Aldeyra Therapeutics, Inc. (?Tenant?), a Delaware corporation. WHEREAS, Original L |
|
| August 5, 2021 |
Exhibit 10.2 Aldeyra Therapeutics, Inc. Amended and Restated Change in Control Plan ARTICLE 1. INTRODUCTION. The Aldeyra Therapeutics, Inc. Amended and Restated Change in Control Plan, as amended and restated from time to time (the ?Plan?) is established effective March 28, 2017 (the ?Effective Date?). The purpose of the Plan is to provide for the accelerated vesting for outstanding (i) unvested e |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA T |
|
| August 5, 2021 |
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights EX-99.1 2 d170530dex991.htm EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights • Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease Expected in Fourth Quarter of 2021 • U.S. FDA Grants Orphan Drug Designation to ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| June 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 (June 8, 2021) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36332 20-1968 |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA |
|
| May 6, 2021 |
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights EX-99.1 2 d940139dex991.htm EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights • Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated with Allergic Conjunctivitis • Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 |
|
| April 29, 2021 |
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock Exhibit 99.1 Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock LEXINGTON, Mass., April 27, 2021 ? Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer |
|
| April 29, 2021 |
10,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254175 PROSPECTUS SUPPLEMENT (To Prospectus dated April 15, 2021) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “ALDX.” On April 28, 2021, the last reported sales price of our common stock on The Nasdaq Capita |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 (April 27, 2021) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36332 20- |
|
| April 29, 2021 |
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock EX-99.2 5 d163605dex992.htm EX-99.2 Exhibit 99.2 Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock LEXINGTON, Mass., April 28, 2021 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, to |
|
| April 29, 2021 |
Exhibit 1.1 10,000,000 Shares ALDEYRA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT April 28, 2021 JEFFERIES LLC SVB LEERINK LLC As the representatives of the several Underwriters (the ?Representatives?) c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: 1. INTRODUCTORY. Aldeyra |
|
| April 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| April 27, 2021 |
Exhibit 99.2 News Release Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis ? Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (p<0.0001) ? Statistical Significance Achieved for Key Secondary Endpoint of Ocular Re |
|
| April 27, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254175 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying |
|
| April 27, 2021 |
Exhibit 99.1 April 27, 2021 DATA RELEASE Top-Line Results from the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis Nasdaq: ALDX ? Aldeyra Therapeutics, Inc. 2021Exhibit 99.1 April 27, 2021 DATA RELEASE Top-Line Results from the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis Nasdaq: ALDX ? Aldeyra Therapeutics, Inc. 2021 Disclaimers and Forward-Looking Statements This presentation and vari |
|
| April 21, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of April 20, 2021, is entered into by and among ALDEYRA THERAPEUTICS INC., a Delaware corporation (?Aldeyra?), Helio Vision, LLC, a Delaware limited liability company, and each of Aldeyra?s Qualified Subsidiaries (hereinafter collectively referred to as the ? |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 13, 2021 |
Aldeyra Therapeutics, Inc. 131 Hartwell Avenue Suite 320 Lexington, MA 02421 Aldeyra Therapeutics, Inc. 131 Hartwell Avenue Suite 320 Lexington, MA 02421 April 13, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento Re: Aldeyra Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-254175) Dear Ms. Sarmento: Pursuant to Rules 460 and 461 under the Securities Act of 19 |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commissi |
|
| March 11, 2021 |
Exhibit 99.1 Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights ? Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021 ? Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials Expected in the Second Half of 2021 ? Projected Cash Runway Through 2023, Including Potential New Drug Application S |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTIC |
|
| March 11, 2021 |
Open Market Sale AgreementSM, dated March 11, 2021, by and between the Registrant and Jefferies LLC. Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM March 11, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Aldeyra Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of t |
|
| March 11, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| February 16, 2021 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 01438T106 (CUSIP Number) December 31, 2020 (Da |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36332 20-1968197 (Commis |
|
| January 14, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226266 PROSPECTUS SUPPLEMENT (To Prospectus dated July 27, 2018) 6,842,106 Shares Common Stock We are offering 6,842,106 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “ALDX.” On January 13, 2021, the last reported sales price of our common stock on The Nasdaq Capital |
|
| January 14, 2021 |
EX-1.1 Exhibit 1.1 6,842,106 Shares ALDEYRA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT January 13, 2021 JEFFERIES LLC SVB LEERINK LLC As the representatives of the several Underwriters (the “Representatives”) c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: 1. INTRODUCTORY. |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 (January 12, 2021) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36332 |
|
| January 14, 2021 |
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 4 d112316dex991.htm EX-99.1 Exhibit 99.1 Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock LEXINGTON, Mass., January 13, 2021 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced |
|
| January 14, 2021 |
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock EX-99.2 5 d112316dex992.htm EX-99.2 Exhibit 99.2 Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock LEXINGTON, Mass., January 13, 2021 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announc |
|
| January 13, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226266 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying |
|
| January 7, 2021 |
EX-99.1 Initial Symptom and Sign Results From Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease DATA RELEASE January 7, 2021 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities |
|
| January 7, 2021 |
EX-99.2 Exhibit 99.2 Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease • Statistical Significance of Reproxalap Over Vehicle Achieved for Ocular Redness, an FDA-Approvable Sign, and Clinical Symptoms of Ocular Dryness and Discomfort • Acute Improvement in Ocular Redness and Symptom Scores Demonstrated Within |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commiss |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDE |
|
| November 5, 2020 |
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update • Initiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020 • Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis Expected to Initiate in the Fourth Quarter of 2020 • Top-line Results from the Phase 3 INVIGORATE Clin |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
Exhibit 10.33 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (“Second Amendment”) is dated as of October 7, 2020 by and between 131 Hartwell LLC, a Massachusetts limited liability company (“Landlord”), successor-in-interest to WLC Three VI, L.L.C., a Delaware limited liability company (“Original Landlord”) and Aldeyra Therapeutics, Inc. (“Tenant”), a Delaware corporation. WHEREAS, Origin |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2020 |
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update • Based on FDA Agreement that RASP is an Objective Sign of Dry Eye Disease, Assessment of Tear RASP Levels in Dry Eye Disease Patients Expected to Begin in the Fourth Quarter of 2020 • New Drug Application (NDA) Submission for Reproxalap in Dry Eye Disease Expected by the End of |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA T |
|
| July 14, 2020 |
EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners Gross Proceeds of Approximately $19.5 Million from At-the-Market Offering Program Sufficient to Extend Operations Through the End of 2022, Including Potential New Drug Application (NDA) Approvals for Reproxalap in Dry Eye Disease and Allergic Conjunctivitis, Based on Current Operating Plans |
|
| July 14, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commi |
|
| July 13, 2020 |
Exhibit 1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| July 13, 2020 |
ALDX / Aldeyra Therapeutics,Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) July 9, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| July 7, 2020 |
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease • Top-Line Results from First of Two Planned Clinical Trials Based on Tear RASP Levels Expected by the End of 2020 • New Drug Application Submission for Reproxalap in Dry Eye Disease Expected by the End of 2021 • Based on Current Operating Plans, Current Cash Expected to Support Ope |
|
| July 7, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 (June 9, 2020) ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36332 20 |
|
| June 4, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| June 4, 2020 |
EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease LEXINGTON, Mass., June 4, 2020 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patient |
|
| May 20, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commis |
|
| May 20, 2020 |
EX-99.1 COVID-19 Development Update May 20, 2020 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020 Systems-Based Approaches for Immunological Disease Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Se |
|
| May 20, 2020 |
EX-99.2 Exhibit 99.2 Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting • ADX-1612 Demonstrates Nanomolar SARS-CoV-2 Antiviral Potency In Vitro • Pending FDA Feedback, IND Submission for ADX-1612 Expected in Third Quarter 2020 • IND Sub |
